Most recently, AAV2-based BDNF gene therapy has been used in a phase I clinical trial to investigate whether it can slow or prevent cell loss in the brain of patients with AD and mild cognitive impairment (NCT05040217). The gene discussed is BDNF; the disease is Alzheimer disease.